Key facts
- Leerink raised Nanobiotix's stock price target.
- The target increase is based on new data for Nanobiotix's cancer drug.
- The adjustment reflects positive R&D pipeline developments.
Investment bank Leerink has raised its stock price target for Nanobiotix. This decision comes after the company released new data concerning its cancer drug. The increased target signifies Leerink's positive assessment of Nanobiotix's research and development progress and its pipeline.